Myelodysplastic Syndrome Clinical Trial

Shwachman Diamond Syndrome Registry and Study

Summary

Shwachman-Diamond syndrome (SDS) is a genetic condition characterized by bone marrow failure, medical co-morbidities, and leukemia predisposition. SDS-Like patients share clinical features with SDS but lack mutations in known SDS genes. Since SDS/SDS-Like syndromes are rare diseases, data are sparse regarding the clinical features, natural history, clinical outcomes with current management, and treatment. For this reason, the SDS Registry was formed to collect clinical data from medical records and to bank biological samples with the goal of understanding SDS/SDS-Like diseases to develop better treatments and improve the health of patients with these conditions.

View Full Description

Full Description

The Shwachman-Diamond Syndrome Registry (SDSR) is dedicated to accelerating research and treatment for SDS to improve survival and quality of life for all patients with the disease. The SDSR is run jointly by Boston Children's Hospital and Cincinnati Children's Hospital Medical Center.

Objective and Aims:

The long term goals of the Registry are to improve diagnosis, inform medical management, and to develop better treatments for SDS and SDS-Like disorders.

To achieve these objectives, the Registry has the following specific aims:

Characterize the natural history, medical complications, and treatment outcomes for patients with SDS and SDS-Like disorders.
Investigate the molecular and genetic pathogenesis of SDS/SDS-Like conditions and their complications such as marrow failure and clonal evolution.
Identify new genes causing SDS/SDS-Like conditions.
Provide education on the diagnosis, medical management and treatment of SDS for patients, families and the medical/scientific community.

Methods: The SDSR collects information from medical records and biological samples. Samples for the SDSR are collected when they are obtained for clinical care so that no extra visits or procedures are needed. These samples may include blood, bone marrow, skin cells, saliva, or discards from other clinical procedures. Family members may also contribute blood samples. All information obtained by the SDSR is housed on a secure, HIPAA-compliant database. No personal information is shared outside of the study team.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria: Shwachman Diamond syndrome, Shwachman-Diamond Syndrome-Like conditions, or a genetically undefined condition that shares clinical features with Shwachman Diamond Syndrome.

Biallelic mutations in SBDS, or pathogenic mutations in DNAJC21, EFL1, or SRP54 OR
Shwachman-Diamond Syndrome defined clinically OR
Clinically suspected Shwachman-Diamond Syndrome OR
Phenotypic features suggestive of SDS OR
Parents, siblings, and other blood relatives of any age, living and deceased, of patients with SDS or SDS-Like conditions are eligible for this study

Exclusion Criteria:

• Patients with other diagnosed causes of bone marrow failure, exocrine pancreatic insufficiency and cancer predisposition will be excluded.

Study is for people with:

Myelodysplastic Syndrome

Estimated Enrollment:

5000

Study ID:

NCT06056908

Recruitment Status:

Recruiting

Sponsor:

Boston Children's Hospital

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 3 Locations for this study

See Locations Near You

Children's Hospital Colorado
Aurora Colorado, 80045, United States More Info
Taizo Nakano, MD
Contact
[email protected]
Boston Children's Hospital
Boston Massachusetts, 02115, United States More Info
Akiko Shimamura, MD, PhD
Contact
[email protected]
Karyn Brundige
Contact
[email protected]
Dana-Farber Cancer Institute
Boston Massachusetts, 02115, United States More Info
Christopher R Reilly, MD
Contact
[email protected]
Cincinnati Children's Hospital Medical Center
Cincinnati Ohio, 45229, United States More Info
Kasiani Myers, MD
Contact
[email protected]
Sara Loveless, RN
Contact
[email protected]

How clear is this clinincal trial information?

Study is for people with:

Myelodysplastic Syndrome

Estimated Enrollment:

5000

Study ID:

NCT06056908

Recruitment Status:

Recruiting

Sponsor:


Boston Children's Hospital

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.